CoChat

Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

Montgomery, Stuart A., Möller, Hans-Jürgen · 2009 · International Clinical Psychopharmacology

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

The methods of assessing the clinical relevance of a significant difference between antidepressants and placebo are discussed. The commonly used criteria of treatment effect and responder rates, as well as the percentage difference in responders between antidepressant and placebo, are critically reviewed and applied to assess the clinical relevance of the significant advantages reported in double-blind, randomized, controlled studies of escitalopram compared with other antidepressants. A significant advantage for escitalopram has been reported in randomized, double-blind, short-term studies compared with citalopram, paroxetine and duloxetine. The reported significant differences are clinically relevant based on a treatment effect difference of at least 2 points on the Montgomery and Asberg Depression Rating Scale as well as a significant advantage in the protocolled responder or remission analysis. The mean unadjusted treatment effect advantage for escitalopram compared with the antidepressants studied is 2.42 points on the Montgomery and Asberg Depression Rating Scale in the short-term treatment. Excluding one study that did not report short-term responder rates, there were significantly more responders on escitalopram (74%) than comparators (63%). Both of these measures demonstrate a clinically relevant difference in favour of escitalopram.

Overview

Integrity signals

Registry

Crossref · 10.1097/yic.0b013e32832a8eb2

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Kennedy, 2006, J Psychiatry Neurosci, 31, 122

Cited by

See all 121

Metadata

Authors
Montgomery, S. A., & Möller, H.-J.
Affiliations
  • University of London (GB)
  • Ludwig-Maximilians-Universität München (DE)
Corresponding author
Montgomery, Stuart A.
Venue
International Clinical Psychopharmacology
Published
2009-05
Volume
24
Issue
3
Pages
111-118
ISSN
0268-1315 (ISSN-L)
OpenAlex
W2051198709
Cited by
121
References
22
Citations by year
2026: 5 · 2025: 5 · 2024: 3 · 2023: 11 · 2022: 4 · 2021: 10 · 2020: 6 · 2019: 7 · 2018: 3 · 2017: 4 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 15 · 2012: 1
FWCI
5.53
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
escitalopram, antidepressants, clinical relevance, treatment effects, responder rate, remission, citalopram, paroxetine, duloxetine, depression, short-term treatment
MeSH terms
Depressive Disorder, Major, Major Depressive Disorder, Depressive Disorder, Humans, Psychiatric Status Rating Scales, Citalopram, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? https://app.cochat.ai/papers/10.1097/yic.0b013e32832a8eb2
The paper
Montgomery, S. A., & Möller, H.-J. (2009). Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e32832a8eb2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.